Search

Your search keyword '"Neaman, Miriam"' showing total 8 results
Start Over Author "Neaman, Miriam"
8 results on '"Neaman, Miriam"'

3. COVID-19 in patients with lymphoproliferative diseases during the Omicron variant surge

Author

Bronstein, Yotam, primary, Gat, Roi, additional, Levi, Shai, additional, Cohen, Yael C., additional, Luttwak, Efrat, additional, Benyamini, Noam, additional, Shragai, Tamir, additional, Vitkon, Roy, additional, Neaman, Miriam, additional, Eilaty, Nili, additional, Levi, Mor, additional, Trestman, Svetlana, additional, Perry, Chava, additional, Herishanu, Yair, additional, and Avivi, Irit, additional

Published
2022
Full Text
View/download PDF

6. Midostaurin in combination with chemotherapy is most effective in patients with acute myeloid leukemia presenting with high FLT3‐ITD allelic ratio who proceed to allogeneic stem cell transplantation while in first complete remission

Author

Ofran, Yishai, primary, Leiba, Ronit, additional, Frisch, Avraham, additional, Horesh, Nurit, additional, Henig, Israel, additional, Yehudai‐Ofir, Dana, additional, Moshe, Yakir, additional, Neaman, Miriam, additional, Ganzel, Chezi, additional, Gal‐Rabinovich, Kinneret, additional, Hellmann, Ilana, additional, Weinstein, Vladimir, additional, Berger, Tamar, additional, and Wolach, Ofir, additional

Published
2020
Full Text
View/download PDF

7. Midostaurin in combination with chemotherapy is most effective in patients with acute myeloid leukemia presenting with high FLT3‐ITD allelic ratio who proceed to allogeneic stem cell transplantation while in first complete remission.

Author

Ofran, Yishai, Leiba, Ronit, Frisch, Avraham, Horesh, Nurit, Henig, Israel, Yehudai‐Ofir, Dana, Moshe, Yakir, Neaman, Miriam, Ganzel, Chezi, Gal‐Rabinovich, Kinneret, Hellmann, Ilana, Weinstein, Vladimir, Berger, Tamar, and Wolach, Ofir

Subjects
ACUTE myeloid leukemia, STEM cell transplantation, COMBINATION drug therapy
Abstract

Objectives: Midostaurin, a multikinase and FLT3 inhibitor, is the first non‐chemotherapy agent approved and widely adopted for the treatment of FLT3‐ITD acute myeloid leukemia (AML). Yet, its role in improving survival of patients referred to allogeneic stem cell transplantation (allo‐SCT) in first complete remission (CR1) needs to be defined. Methods: This multicenter study retrospectively evaluated the outcome of 119 FLT3‐ITD AML patients [59 (49.6%) males and 60 females] intensively treated between 2015 and 2019 at five Israeli centers. In our cohort, allo‐SCT in CR1 was widely implemented (47%) and patient stratification was based on the current allelic ratio (AR) cutoff of 0.5. Results: Ninety‐eight patients (82.3%) achieved CR1/CR with incomplete count recovery (CRi). Death during induction was reported in 7 (5.9%) patients. In multivariate analysis, midostaurin use and allo‐SCT in CR1 were the most significant factors affecting overall survival (OS). Midostaurin incorporation in chemotherapy regimens significantly improved CR + CRi rates (P =.002), reduced relapse rates (P =.02), and was remarkably advantageous for high‐AR patients (2‐year OS 82%). In low‐AR patients, the midostaurin effect was much less prominent. Conclusions: Our results demonstrate benefits of midostaurin incorporation in intensive chemotherapy regimens, particularly for high‐AR AML patients to whom it should be offered along with allo‐SCT in CR1. [ABSTRACT FROM AUTHOR]

Published
2021
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results